97 related articles for article (PubMed ID: 8713775)
1. Safety profile of porcine factor VIII and its use as hospital and home-therapy for patients with haemophilia-A and inhibitors: the results of an international survey.
Hay CR; Lozier JN; Lee CA; Laffan M; Tradati F; Santagostino E; Ciavarella N; Schiavoni M; Fukui H; Yoshioka A; Teitel J; Mannucci PM; Kasper CK
Thromb Haemost; 1996 Jan; 75(1):25-9. PubMed ID: 8713775
[TBL] [Abstract][Full Text] [Related]
2. Use of porcine factor VIII for surgical procedures in hemophilia A patients with inhibitors.
Lozier JN; Santagostino E; Kasper CK; Teitel JM; Hay CR
Semin Hematol; 1993 Apr; 30(2 Suppl 1):10-21. PubMed ID: 8480192
[TBL] [Abstract][Full Text] [Related]
3. Porcine factor VIII therapy in patients with congenital hemophilia and inhibitors: efficacy, patient selection, and side effects.
Hay CR; Lozier JN; Lee CA; Lafan M; Tradati H; Santagostino E; Ciavarella N; Schiavoni M; Fukui H; Yoshioka A
Semin Hematol; 1994 Apr; 31(2 Suppl 4):20-5. PubMed ID: 7939768
[No Abstract] [Full Text] [Related]
4. Adverse effects of treatment with porcine factor VIII.
Gringeri A; Santagostino E; Tradati F; Giangrande PL; Mannucci PM
Thromb Haemost; 1991 Mar; 65(3):245-7. PubMed ID: 1904652
[TBL] [Abstract][Full Text] [Related]
5. The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experience.
Brettler DB; Forsberg AD; Levine PH; Aledort LM; Hilgartner MW; Kasper CK; Lusher JM; McMillan C; Roberts H
Arch Intern Med; 1989 Jun; 149(6):1381-5. PubMed ID: 2499293
[TBL] [Abstract][Full Text] [Related]
6. [Comparison of anti-human and anti-porcine factor VIII antibody titers in patients with hemophilia].
Windyga J; Rzymkiewicz L; Lopaciuk S
Acta Haematol Pol; 1996; 27(1):27-31. PubMed ID: 8629440
[TBL] [Abstract][Full Text] [Related]
7. Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation.
Hay CR; Ludlam CA; Colvin BT; Hill FG; Preston FE; Wasseem N; Bagnall R; Peake IR; Berntorp E; Mauser Bunschoten EP; Fijnvandraat K; Kasper CK; White G; Santagostino E
Thromb Haemost; 1998 Apr; 79(4):762-6. PubMed ID: 9569189
[TBL] [Abstract][Full Text] [Related]
8. Use of porcine factor VIII in the management of seventeen patients with factor VIII antibodies.
Gatti L; Mannucci PM
Thromb Haemost; 1984 Jul; 51(3):379-84. PubMed ID: 6437005
[TBL] [Abstract][Full Text] [Related]
9. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.
Hay CR; Brown S; Collins PW; Keeling DM; Liesner R
Br J Haematol; 2006 Jun; 133(6):591-605. PubMed ID: 16704433
[TBL] [Abstract][Full Text] [Related]
10. The evidence behind inhibitor treatment with porcine factor VIII.
Lee CA
Pathophysiol Haemost Thromb; 2002; 32 Suppl 1():5-8. PubMed ID: 12214138
[TBL] [Abstract][Full Text] [Related]
11. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate.
Peerlinck K; Arnout J; Gilles JG; Saint-Remy JM; Vermylen J
Thromb Haemost; 1993 Feb; 69(2):115-8. PubMed ID: 8456422
[TBL] [Abstract][Full Text] [Related]
12. Safety, efficacy and cost-effectiveness of home therapy with recombinant activated factor VII in a patient with severe haemophilia A and an anti-factor VIII inhibitor.
Stewart AJ; Hanley JP; Ludlam CA
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S93-5. PubMed ID: 9819036
[TBL] [Abstract][Full Text] [Related]
13. Continuous infusion of porcine factor VIII in patients with haemophilia A and high-responding inhibitors: stability and clinical experience.
O'Gorman P; Dimichele DM; Kasper CK; Mannucci PM; Santagostini E; Hay CR
Haemophilia; 2001 Nov; 7(6):537-43. PubMed ID: 11851750
[TBL] [Abstract][Full Text] [Related]
14. Hemophilia. Strategies for the treatment of inhibitor patients.
Ingerslev J
Haematologica; 2000 Oct; 85(10 Suppl):15-20. PubMed ID: 11187863
[TBL] [Abstract][Full Text] [Related]
15. Inhibitors in young boys with haemophilia.
Lusher JM
Baillieres Best Pract Res Clin Haematol; 2000 Sep; 13(3):457-68. PubMed ID: 11030045
[TBL] [Abstract][Full Text] [Related]
16. Home treatment of haemophilia. A follow-up study.
Ekert H; Moorehead M; Williamson G
Med J Aust; 1981 Jul; 2(1):21-3. PubMed ID: 6792476
[TBL] [Abstract][Full Text] [Related]
17. Porcine factor VIII: past, present and future.
Hay CR
Haematologica; 2000 Oct; 85(10 Suppl):21-4; discussion 24-5. PubMed ID: 11187865
[TBL] [Abstract][Full Text] [Related]
18. Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate.
Gringeri A; Monzini M; Tagariello G; Scaraggi FA; Mannucci PM;
Haemophilia; 2006 Mar; 12(2):128-32. PubMed ID: 16476086
[TBL] [Abstract][Full Text] [Related]
19. New protocol for immune tolerance induction in acquired hemophilia.
Nemes L; Pitlik E
Haematologica; 2000 Oct; 85(10 Suppl):64-8. PubMed ID: 11187874
[TBL] [Abstract][Full Text] [Related]
20. Low risk of inhibitor formation in haemophilia patients after a change in treatment from Chinese hamster ovary cell-produced to baby hamster kidney cell-produced recombinant factor VIII.
Singleton E; Smith J; Kavanagh M; Nolan B; White B
Thromb Haemost; 2007 Dec; 98(6):1188-92. PubMed ID: 18064312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
